Disease Overview：Multiple Endocrine Neoplasia（MEN）
Multiple Endocrine Neoplasia (MEN) is a group of rare, autosomal dominant hereditary syndromes characterized by the development of tumors in two or more endocrine glands. The most common subtypes are MEN1 (associated with mutations in the *MEN1* tumor suppressor gene) and MEN2 (driven by *RET* proto-oncogene mutations), each with distinct clinical profiles: MEN1 typically involves parathyroid adenomas, pancreatic neuroendocrine tumors (e.g., gastrinomas, insulinomas), and pituitary adenomas; MEN2 features medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism. Early genetic testing, lifelong surveillance, and timely surgical intervention—such as prophylactic thyroidectomy in *RET*-positive MEN2 families—are critical to prevent metastasis and improve survival. Management requires multidisciplinary coordination among endocrinologists, endocrine surgeons, nuclear medicine specialists, and genetic counselors.
China offers compelling advantages for MEN care: leading academic hospitals—including Peking Union Medical College Hospital and Shanghai Ruijin Hospital—host nationally accredited Endocrine & Metabolic Disease Centers with extensive experience in complex MEN diagnostics and minimally invasive parathyroidectomy, laparoscopic adrenalectomy, and MTC-directed surgery. Advanced molecular profiling, next-generation sequencing for germline *RET/MEN1* analysis, and peptide receptor radionuclide therapy (PRRT) for advanced neuroendocrine disease are widely available. Five-year disease-free survival rates for early-stage MEN-related tumors align with international benchmarks, supported by over 200 documented successful cases annually across tier-1 centers. Treatment costs in China average 40–60% lower than in the US or Western Europe, without compromising quality—CT/MRI, intraoperative PTH monitoring, and postoperative calcitonin surveillance are standardized and reimbursed under national protocols.
As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying physician credentials, coordinating appointments at JCI-accredited institutions, providing itemized, transparent pricing in advance, arranging visa support, interpreters, and post-treatment follow-up—all tailored to the longitudinal nature of MEN management.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Multiple Endocrine Neoplasia (MEN)
Non-Surgical / Medical Management
*Target Criteria:* Asymptomatic carriers, mild biochemical abnormalities, contraindications to surgery, or preoperative stabilization.
- •Somatostatin analogs (e.g., octreotide LAR)
- *Cost:* ¥3,200–¥4,800/dose (≈ $445–$670) × every 4 weeks
- •Dopamine agonists (cabergoline)
- *Cost:* ¥180–¥320/month (≈ $25–$45)
- •Calcimimetics (cinacalcet)
- *Cost:* ¥420–¥650/month (≈ $59–$91)
- •Baseline labs & imaging (annual):
- Abdominal MRI (pancreas/liver) — ¥1,200 (≈ $168) - Neck ultrasound + parathyroid sestamibi scan — ¥1,650 (≈ $230)
Surgical / Interventional Options
*Eligibility:* Biochemically confirmed hormone excess, tumor ≥1 cm, progressive growth, or malignant features.
- •Parathyroidectomy (4-gland exploration ± autotransplant)
- *Procedure cost:* ¥28,000–¥42,000 (≈ $3,900–$5,850)
- •Distal pancreatectomy (for non-metastatic insulinoma/GEP-NET)
- *Procedure cost:* ¥45,000–¥68,000 (≈ $6,270–$9,470)
- •Transsphenoidal resection (pituitary adenoma)
- *Procedure cost:* ¥32,000–¥51,000 (≈ $4,460–$7,100)
Special / Complex Condition Management
- •Metastatic pancreatic NET (liver-dominant):
- •MEN2A with RET p.C634 mutation (prophylactic thyroidectomy):
- •Adrenal pheochromocytoma resection (laparoscopic):
- Procedure cost: ¥41,000–¥63,000 (≈ $5,710–$8,770)
Quick Selection Guide
- •<30 years, RET+ (MEN2A): Prophylactic thyroidectomy ($5,010–$7,520) — *optimal for cancer prevention.*
- •Age 45–65, MEN1 with multiple small pancreatic NETs: Surveillance + somatostatin analogs ($445–$670/month) — *avoids overtreatment.*
- •Severe hypercalcemia (>11.5 mg/dL) + renal stones: Urgent parathyroidectomy ($3,900–$5,850) — *first-line definitive therapy.*
- •Limited budget (<$3,000), stable MEN1: Annual labs + abdominal MRI ($222/year) + cabergoline if prolactinoma present ($25–$45/month).
- •Comorbidities (COPD, CHF): Medical stabilization (cinacalcet + hydration) before surgical clearance — *reduces perioperative risk.*
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Multiple Endocrine Neoplasia Medical Vacation Packages
Curated transparent all-inclusive packages combining Multiple Endocrine Neoplasia treatment with China top medical destinations:
